New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
09:25 EDTACAD, ACAD, ACAD, JAZZ, JAZZ, JAZZ, FRX, FRX, FRX, MDCO, MDCO, MDCO, SLXP, SLXP, SLXP, VRX, VRX, VRX, VRTX, VRTX, VRTX, SGMO, SGMO, SGMO, PCYC, PCYC, PCYC, PDLI, PDLI, PDLI, ISIS, ISIS, ISIS, HZNP, HZNP, HZNP, GILD, GILD, GILD, CELG, CELG, CELG, BIIB, BIIB, BIIB, BDSI, BDSI, BDSI, NKTR, NKTR, NKTRPiper Jaffray's technical analyst holds an analyst/industry conference call
Senior Technical Analyst Johnson provides an overview of the firm's covered universes, Biotech & Specialty Pharmaceuticals, from the viewpoint of a technical analyst on an Analyst/Industry conference call to be held on January 21 at 10 am.
News For ACAD;BDSI;BIIB;CELG;GILD;HZNP;ISIS;PDLI;PCYC;SGMO;VRTX;VRX;SLXP;MDCO;FRX;JAZZ;NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
February 18, 2015
15:35 EDTPCYCNotable companies reporting after market close
Subscribe for More Information
10:48 EDTSLXPSalix valuation, litigation influencing potential buyers, dealReporter says
Subscribe for More Information
10:32 EDTSLXPOptions with decreasing implied volatility
Subscribe for More Information
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTCELGCelgene reports FDA expands indication for Revlimid combo
Subscribe for More Information
09:37 EDTGILD, CELGOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
09:04 EDTVRTXVertex data likely to show lung function improvement, says JMP Securities
Subscribe for More Information
08:54 EDTMDCOThe Medicines Co. anticipates potential partnership talks
Subscribe for More Information
08:52 EDTMDCOThe Medicines Co. anticipates four U.S. FDA approvals in 2015
08:41 EDTMDCOThe Medicines Co. says not giving financial guidance due to Hospira suit
Subscribe for More Information
07:01 EDTMDCOThe Medicines Co. reports Q4 adjusted EPS 20c, consensus (82c)
Subscribe for More Information
06:47 EDTCELGCelgene initiated with a Buy at Canaccord
Target $156.
February 17, 2015
18:17 EDTSLXP, VRXJANA Partners gives quarterly update on stakes
NEW STAKES: NCR (NCR), Liberty Ventures (LVNTA), Solarcity (SCTY), Computer Sciences Corp (CSC), Salix (SLXP), and Applied Materials (AMAT). INCREASED STAKES: Hertz (HTZ), Valeant (VRX), Walgreens Boots Alliance (WBA), Rackspace (RAX), and HD Supply (HDS). DECREASED STAKES: AIG (AIG), Actavis (ACT), Charter (CHTR), AerCap (AER), and Energy Transfer Equity (ETE). LIQUIDATED STAKES: Equinix (EQIX), Cameron International (CAM), Dollar General (DG), QEP Resources (QEP), and Amgen (AMGN).
18:06 EDTSLXPPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:13 EDTGILD, VRXPoint72 gives quarterly update on stakes
Subscribe for More Information
16:00 EDTGILDOptions Update; February 17, 2015
Subscribe for More Information
13:18 EDTGILDOmega Advisors gives quarterly update on stakes
Subscribe for More Information
10:51 EDTSLXPOptions with decreasing implied volatility
Subscribe for More Information
09:40 EDTGILDActive equity options trading on open
Subscribe for More Information
09:05 EDTPCYCPharmacyclics announces positive results from treatment with IMBRUVICA
Pharmacyclics announced that treatment with IMBRUVICA was associated with an 88% overall response rate, or ORR, with a median time on study of 23.3 months, in 16 patients with relapsed/refractory, or R/R, high-risk chronic lymphocytic leukemia. These patients had a median of five prior therapies and 63% were high-risk del 17p CLL patients. The estimated median progression-free survival, or PFS, at 24 months was 76.6%. All patients had previously undergone allogeneic stem cell transplant, a procedure in which stem cells from one person are transplanted to another. A second presentation during the BMT Tandem meeting highlighted data from five patients with R/R CLL who had undergone allo-HCT. The researchers concluded that these results support further study of IMBRUVICA in patients following allo-HCT, including those patients with chronic GVHD. Study PCYC 1129, a multicenter open--label Phase Ib/II study of IMBRUVICA in steroid--dependent or refractory chronic GVHD patients, has completed its Phase Ib without dose limiting toxicities and is now enrolling the Phase II portion at the recommended Phase II dose of 420 mg.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use